Curcumin modulation of the activation of PYK2 in peripheral blood mononuclear cells from patients with lupus nephritis
More details
Hide details
Submission date: 2017-09-22
Final revision date: 2017-11-26
Acceptance date: 2017-12-01
Online publication date: 2017-12-30
Publication date: 2017-12-31
Reumatologia 2017;55(6):269–275
Introduction: Proline-rich tyrosine kinase 2 (PYK2) provides important signals during the activation of lymphocytes, which is essential in autoimmune diseases. Systemic lupus erythematosus (SLE) is a representative autoimmune disease, and lupus nephritis (LN) is one of its most severe complications. Although glucocorticoid-binding immuno-suppression is the first-line therapy for patients with LN, the common and severe side effects of such treatment call for new strategies to improve long-term prognosis and life quality for these patients. Curcumin has been used to treat autoimmune disease with good curative effect, but little is known about the effect of curcumin on LN patients. Our aim was to investigate the mechanism of curcumin for management of LN, specifically regarding the PYK2 pathways.
Material and methods: Freshly isolated peripheral blood mononuclear cells (PBMCs) from 20 LN patients and 20 healthy individuals were cultured and stimulated with either PMA, PMA+TyrA9 (PYK2 specific inhibitor), or PMA+Curcumin, and with PBS as control. After 48 hours of incubation, cells were harvested and the expression of PYK2, p-PYK2, CD40L, CTLA-4, and PBMCs proliferation were measured. Then the expression and activation of PYK2 was evaluated using Western blot, the expression of costimulatory molecules CD40L and CTLA-4 protein was evaluated using flow cytometry, and PBMC proliferation was assessed using a [3H]-thymidine incorporation assay.
Results: Curcumin inhibited the expression and activation of PYK2 in PBMCs in patients with LN in vitro. The inhibition rate of curcumin was negatively correlated with the level of serum complement, but positively correlated with 24-h proteinuria. Curcumin also suppressed the expression of costimulatory molecules CD40L and CTLA-4, as well as PBMC proliferation. Interestingly, these effects were not reproduced on PBMC cultures of healthy subjects.
Conclusions: The inhibition of PYK2 signalling protein may be one of the mechanisms underlying the action of curcumin in LN treatment.
Paley MA, Strand V, Kim AH. From mechanism to therapies in systemic lupus erythematosus. Curr Opin Rheumatol 2017; 29: 178-186.
Jordan N, D’Cruz D. Current and emerging treatment options in the management of lupus. Immunotargets Ther 2016; 5: 9-20.
Abarikwu SO, Akiri OF, Durojaiye MA, Alabi AF. Combined administration of curcumin and gallic acid inhibits gallic acid-induced suppression of steroidogenesis, sperm output, antioxidant defenses and inflammatory responsive genes. J Steroid Biochem Mol Biol 2014; 143: 49-60.
Jeong CW, Yoo KY, Lee SH, et al. Curcumin protects against regional myocardial ischemia/reperfusion injury through activation of RISK/GSK-3 and inhibition of p38 MAPK and JNK.
J Cardiovasc Pharmacol Ther 2012; 17: 387-394.
Nayak AP, Mills T, Norton I. Lipid Based Nanosystems for Curcumin: Past, Present and Future. Curr Pharm Des 2016; 22: 4247-4256.
Jagetia GC, Aggarwal BB.“Spicing up”of the immune system by curcumin. J Clin Immunol 2007; 27: 19-35.
Shirley SA, Montpetit AJ, Lockey RF, Mohapatra SS. Curcumin prevents human dendritic cell response to immune stimulants. Biochem Biophys Res Commu 2008; 374: 431-436.
Handono K, Pratama MZ, Endharti AT, Kalim H. Treatment of low doses curcumin could modulate Th17/Treg balance specifically on CD4+ T cell cultures of systemic lupus erythematosus patients. Cent Eur J Immunol 2015; 40: 461-469.
Pollard KM, Arnush M, Hultman P, Kono DH. Costimulation requirements of induced murine systemic autoimmune disease. J Immunol 2004; 173: 5880-5887.
Yi Y, McNerney M, Datta SK. Regulatory defects in Cbl and mitogen-activated protein kinase (extracellular signal-related kinase) pathways cause persistent hyperexpression of CD40 ligand in human lupus T cells. J Immunol 2000; 165: 6627-6634.
Wong CK, Lit LC, Tam LS, et al. Aberrant production of soluble costimulatory molecules CTLA-4,CD28,CD80 and CD86 in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2005; 44: 989-994.
Mohan C, Shi Y, Laman JD, Datta SK. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol 1995; 154: 1470-1480.
Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994; 265: 1225-1227.
Sasaki H, Nagura K, Ishino M, et al. Cloning and characterization of cell adhesion kinase, a novel protein-tyrosine kinase of the focal adhesion kinase subfamily. Journal of Biological Chemistry 1995; 270: 21206-21219.
Takagi C, Ueki K, Ikeuchi H, et al. Increased expression of cell adhesion kinase beta in human and rat crescentic glomerulonephritis. Am J Kidney Dis 2002; 39: 174-182.
Shahrara S, Castro-Rueda HP, Haines GK, Koch AE. Differential expression of the FAK family kinases in rheumatoid arthritis and osteoarthritis synovial tissues. Arthritis Res Ther 2007; 9: R112.
Lin WN, Luo SF, Wu CB, et al. Lipopolysaccharide induces VCAM-1 expression and neutrophil adhesion to human tracheal smooth muscle cells: involvement of Src/EGFR/ PI3-K/Akt pathway. Toxicol Appl Pharmacol 2008; 228: 256-268.
Koh YH, Che W, Higashiyama S, et al. Osmotic stress induces HB-EGF gene expression via Ca(2+)/Pyk2/JNK signal cascades in rat aortic smooth muscle cells. J Biochem 2001; 130: 351-358.
Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-640.
Arora R, Kuhad A, Kaur IP, Chopra K. Curcumin loaded solid lipid nanoparticles ameliorate adjuvant-induced arthritis in rats. Eur J Pain 2015; 19: 940-952.
Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS 2013; 15: 195-218.
Chen FY, Zhou J, Guo N, et al. Curcumin retunes cholesterol transport homeostasis and inflammation response in M1 macrophage to prevent atherosclerosis. Biochem Biophys Res Commun 2015; 467: 872-878.
Castangia I, Nácher A, Caddeo C, et al. Fabrication of quercetin and curcumin bionanovesicles for the prevention and rapid regeneration of full-thickness skin defects on mice. Acta Biomate 2014; 10: 1292-1300.
Lee GH, Lee HY, Choi MK, et al. Protective effect of Curcuma longa L. extract on CCl4- induced acute hepatic stress. BMC Res Notes 2017; 10: 77.
Tokac M, Taner G, Aydin S, et al. Protective effects of curcumin against oxidative stress parameters and DNA damage in the livers and kidneys of rats with biliary obstruction. Food Chem Toxicol 2013; 61: 28-35.
Kim G, Jang MS, Son YM, et al. Curcumin inhibits CD4(+) T cell activation, but augments CD69 expression and TGF-1-mediated generation of regulatory T cells at late phase. PLoS On 2013; 8: e62300.
Sebastià N, Soriano JM, Barquinero JF, et al. In vitro cytogenetic and genotoxic effects of curcumin on human peripheral blood lymphocytes. Food Chem Toxicol 2012; 50: 3229-3233.
Zhao HM, Han F, Xu R, et al. Therapeutic effect of curcumin on experimental colitis mediated by inhibiting CD8+CD11c+ cells. World J Gastroenterol 2017; 23: 1804-1815.
Merrill JT. Co-stimulatory molecules as targets for treatment of lupus. Clin Immunol 2013; 148: 369-375.
Linsley PS, Greene JL, Tan P, et al. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J Exp Med 1992; 176: 1595-1604.
Sharma S, Chopra K, Kulkarni SK, Agrewala JN. Resveratrol and curcumin suppress immune response through CD28/CTLA-4 and CD80 co-stimulatory pathway. Clin Exp Immunol 2007; 147: 155-163.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.